GLPwatch
Corrigendum: Safety of Semaglutide.
Front Endocrinol (Lausanne) · 2021
Last updated 2026-08-28| Journal | Front Endocrinol (Lausanne), 2021 |
|---|---|
| Citations | 14 |
| Relative citation ratio | 0.87 |
| NIH percentile | 46 |
| Molecules | semaglutide |
Abstract
[This corrects the article DOI: 10.3389/fendo.2021.645563.].
Verbatim abstract via PubMed 34858353 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.